Cargando…

Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy

Mortality associated with pancreatic cancer is among the highest of all malignancies, with a 5-year overall survival of 5–10%. Immunotherapy, represented by the blocking antibodies against programmed cell death protein 1 or its ligand 1 (anti-PD-(L)1), has achieved remarkable success in a number of...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lingyue, Huang, Xing, Shi, Fukang, Song, Jinyuan, Guo, Chengxiang, Yang, Jiaqi, Liang, Tingbo, Bai, Xueli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827285/
https://www.ncbi.nlm.nih.gov/pubmed/35139879
http://dx.doi.org/10.1186/s13046-022-02273-w